Your browser doesn't support javascript.
loading
Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 894-898, 2020.
Article in Chinese | WPRIM | ID: wpr-827189
ABSTRACT
OBJECTIVE@#To investigate the influence of conventional CAG regimen and decitabine + decreased dose CAG (D+dCAG) regimen on the clinical efficacy and safety of patients with MDS-RAEB/AML-MRC.@*METHODS@#The clinical data of 67 patients with MDS-RAEB/AML-MRC hospitalized in our hospital from March 2012 to July 2017 were analyzed retrospectively. According to chemotherapecctic regimens, 76 patients were divided into 2 groups 37 patients treated with conventional CAG regimen were enrolled in control group, 30 patients treated with decitabine + decreased dose CAG regimen were enrolled in D+dCAG group. The complete remission (CR) rate, overall remission rate (ORR), OS and PFS time and incidence of adverse reactions in 2 groups were compared.@*RESULTS@#The CR in D+dCAG group was significantly higher than that in control group (P<0.05). ORR was not significanly different between 2 groups (P>0.05). There was no significant difference in the cumulative OS rate between 2 groups (P>0.05). There was no significant difference in the cumulative OS rate and PFS rate in nonimplantation between 2 groups (P>0.05). The incidence of adverse reactions of hematological system, pulmonary infection, skin and soft tissue infection, agranulocytosic fever and mycotic infection was not significanly different between 2 groups (P>0.05). The duration of granulocyte deficiency and platelet count less than 20×10/L were not significanly different between 2 groups (P>0.05).@*CONCLUSION@#Compared with conventional CAG regimen, decitabine + decreased dose CAG regimen in the treatment of patients with MDS-RAEB/AML-MRC can efficiently improve the remission effects and showed the well overall safety, but can not increase the survival rate.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Myelodysplastic Syndromes / Anemia, Refractory, with Excess of Blasts / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Granulocyte Colony-Stimulating Factor / Treatment Outcome / Cytarabine / Decitabine Type of study: Observational study Limits: Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Myelodysplastic Syndromes / Anemia, Refractory, with Excess of Blasts / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Granulocyte Colony-Stimulating Factor / Treatment Outcome / Cytarabine / Decitabine Type of study: Observational study Limits: Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2020 Type: Article